NCT07285213

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-12-10Est. Completion: 2027-04-20

Enrollment target: 230 participants

Locations

Research Site, Phoenix, Arizona, United States
Research Site, Chula Vista, California, United States
Research Site, Sacramento, California, United States
Research Site, Torrance, California, United States
Research Site, Hamden, Connecticut, United States
Research Site, Gainesville, Florida, United States
Research Site, Hialeah, Florida, United States
Research Site, Homestead, Florida, United States
Research Site, Jacksonville, Florida, United States
Research Site, Miami Lakes, Florida, United States
Research Site, Miramar, Florida, United States
Research Site, Port Orange, Florida, United States
Research Site, Tamarac, Florida, United States
Research Site, Tampa, Florida, United States
Research Site, Athens, Georgia, United States
Research Site, Atlanta, Georgia, United States
Research Site, Idaho Falls, Idaho, United States
Research Site, Burr Ridge, Illinois, United States

Other microbiome trials you might be interested in

VE303 for Prevention of Recurrent Clostridioides Difficile InfectionPhase 3Recruiting

Clostridium DifficileClostridium Difficile InfectionsClostridium Difficile Infection RecurrenceClostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceCDIC. Diff InfectionRecurrent Clostridium Difficile InfectionC.Difficile DiarrheaDiarrhea Infectious

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (…

Huntsville, United StatesEst. completion Jun 2027

View Trial →

Outcomes of Outpatients in an Gut Microbiota ClinicRecruiting

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.